Clinical Trial Update: TAK-700 in Castration Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of TAK-700 (orteronel) for castration-resistant prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• TAK-700 (Orteronel)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Prostate Cancer | Phase 2 | Status: WITHDRAWN